Whats new in regulatory science

Office of Translational Sciences (OTS) – CDER

Promotes and Protects Public Health by:

  • scientific collaboration and innovation in drug regulatory review
  • validity of clinical trial design and analysis
  • quantitative and statistical approaches to decision making
  • alignment of CDER research with CDER goals
  • establishing technology transfer agreements
  • knowledge management databases
  • bioequivalence inspections

Offices:

Office of Biostatistics

Office of Computational Science

Office of Clinical Pharmacology

Office of Study and Integrity and Surveillance

LEARN

Published by Drug & Device Advisory Group


Leave a Reply


Fill in your details below or click an icon to log in:

Gravatar

WordPress.com Logo



You are commenting using your WordPress.com account.
( Log Out / 
Change )

Google photo



You are commenting using your Google account.
( Log Out / 
Change )

Twitter picture



You are commenting using your Twitter account.
( Log Out / 
Change )

Facebook photo



You are commenting using your Facebook account.
( Log Out / 
Change )

Cancel

Connecting to %s